Clinical Trials
26 trialsNCT04248829 2026-05-28
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Yuhan Corporation
Phase 3 Completed
NCT02296125 2026-04-21
FLAURA
AstraZeneca
Phase 3 Completed
NCT02411448 2026-01-16
RELAY
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03787992 2025-04-11
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAG)
Allist Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT02588261 2024-12-10
SOLAR
Astellas Pharma Inc
Phase 3 Terminated
NCT03866499 2024-08-07
A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients
Beta Pharma, Inc.
Phase 3 Active not recruiting
NCT04143607 2024-06-14
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT01774721 2023-11-14
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer
Phase 3 Completed
NCT03849768 2023-01-20
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT01544179 2020-09-25
IMPRESS
AstraZeneca
Phase 3 Completed
NCT04239833 2020-01-27
A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 3 Unknown
NCT03529084 2019-11-22
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
Novartis
Phase 3 Withdrawn
NCT03856697 2019-02-27
Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Phase 3 Unknown
NCT00357734 2016-08-30
Iressa Follow-up Trial
AstraZeneca
Phase 3 Completed
NCT01017874 2015-07-08
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
Eli Lilly and Company
Phase 3 Completed
NCT01040780 2014-02-14
ICOGEN
Betta Pharmaceuticals Co., Ltd.
Phase 3 Completed
NCT00322452 2013-11-07
IPASS
AstraZeneca
Phase 3 Completed
NCT00090675 2013-01-29
IMAC/Herbst
AstraZeneca
Phase 3 Withdrawn
NCT00034879 2013-01-04
Iressa Expanded Access Program (EAP)
AstraZeneca
Phase 3 Completed
NCT00478049 2012-06-06
ISTANA
AstraZeneca
Phase 3 Completed
NCT00234468 2011-05-20
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
AstraZeneca
Phase 3 Terminated
NCT00076388 2011-05-13
Iressa Versus Docetaxel (Taxotere)
AstraZeneca
Phase 3 Completed
NCT00206219 2011-01-27
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
AstraZeneca
Phase 3 Completed
NCT00635973 2009-04-22
Open-Label Extension of Other SZ1839 (Iressa) Trials
AstraZeneca
Phase 3 Completed
NCT00080340 2008-01-15
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Telik
Phase 3 Completed
NCT00252707 2007-12-18
Iressa 2nd Line Phase III Study in Japan
AstraZeneca
Phase 3 Completed